MODELLING

From 2009.igem.org

(Difference between revisions)
 
(56 intermediate revisions not shown)
Line 1: Line 1:
-
'''Bold text'''== MODELLING ==
+
<html>
-
<html>
+
<body style="background-color:#006380">
<body style="background-color:#006380">
 +
 +
<html>
 +
<div align="center"><a href="https://2009.igem.org/Team:METU-Gene/Events_in_Wound_Dressing"><img src="https://static.igem.org/mediawiki/2009/d/d4/Events_in_WDk.gif"
 +
    style="width:15%; height:150px; border:2px solid #aaa; margin:-10px 5px 10px 15px;"
 +
          title="Events in Wound Dressing">
 +
<a href="https://2009.igem.org/Team:METU-Gene/Working_Mechanism"><img src="https://static.igem.org/mediawiki/2009/b/b5/Workingmechk.gif"
 +
    style="width:15%; height:150px; border:2px solid #aaa; margin:-10px 5px 10px 0px;"
 +
          title="Working Mechanism">
 +
<a href="https://2009.igem.org/Team:METU-Gene/Methods_and_Results"><img src="https://static.igem.org/mediawiki/2009/6/6f/METHODSANDRESULTSk.jpg"
 +
    style="width:15%; height:150px; border:2px solid #aaa; margin:-10px 5px 10px 0px;"
 +
          title="Methods and Results">
 +
<a href="https://2009.igem.org/Index-4.html"><img src="
 +
https://static.igem.org/mediawiki/2009/1/19/MODELLingy.gif"
 +
    style="width:15%; height:150px; border:2px solid #aaa; margin:-10px 5px 10px 0px;"
 +
          title="Modelling of Mechanism">
 +
<a href="https://2009.igem.org/2009.igem.org/metu-gene/parts"><img src="https://static.igem.org/mediawiki/2009/6/6a/Ads%C4%B1zk.jpg"
 +
    style="width:15%; height:15%; border:2px solid #aaa; margin:-10px 5px 10px 0px;"
 +
          title="Constructed Devices">
 +
<a href="https://2009.igem.org/Team:METU-Gene/Focus_on_our_Future"><img src="
 +
https://static.igem.org/mediawiki/2009/0/06/Focus_Logok.jpg"
 +
    style="width:150px; height:150px; border:4px solid #aaa; margin:-10px 5px 10px 0px;"
 +
    title="Focus on our Future!"></a></div></html>
 +
 +
 +
 +
== Wound Dressing Mechanism ==
 +
 +
 +
<html><div align="center" style="margin:15px 0px 0px 0px"><a href="https://2009.igem.org/2009.igem.org/metu-gene/parts"><img style="border: 0px solid ; width: 900px; height: 500px;" alt="w7" src="http://partsregistry.org/wiki/images/5/59/Mm.jpg"></a></div>
</html>
</html>
-
  http://partsregistry.org/wiki/images/5/59/Mm.jpg
+
 
----
----
-
<!-- ***** New entry ***** -->
+
 
-
'''Wound Dressing Layer Design'''
+
== Wound Dressing Layer Design ==
<div>Rapid and proper healing is important in the treatment of wounds such as severe burns, trauma, diabetic,decubitus and venous stasis ulcers, and similar tissue damages. In cases of severe and large amounts of skin loss, or in the presence of difficult and non-healing wounds, immediate coverage of the wound surface with a dressing is needed. The dressing achieves the functions of the natural skin by protecting the area from the loss of fluid and proteins, preventing infection through bacterial invasion, and subsequent tissue damage. In some cases, it improves healing by providing a support for the proliferating cells.</div>
<div>Rapid and proper healing is important in the treatment of wounds such as severe burns, trauma, diabetic,decubitus and venous stasis ulcers, and similar tissue damages. In cases of severe and large amounts of skin loss, or in the presence of difficult and non-healing wounds, immediate coverage of the wound surface with a dressing is needed. The dressing achieves the functions of the natural skin by protecting the area from the loss of fluid and proteins, preventing infection through bacterial invasion, and subsequent tissue damage. In some cases, it improves healing by providing a support for the proliferating cells.</div>
-
 
-
 
<html><div align="center"> <a href="https://2009.igem.org/Team:METU-Gene/Gelatin_Sponge"><img src="https://static.igem.org/mediawiki/2009/0/06/Gltn.jpg"
<html><div align="center"> <a href="https://2009.igem.org/Team:METU-Gene/Gelatin_Sponge"><img src="https://static.igem.org/mediawiki/2009/0/06/Gltn.jpg"
Line 21: Line 47:
<a href="https://2009.igem.org/Team:METU-Gene/Biomaterial_Search"><img src="https://static.igem.org/mediawiki/2009/a/a1/Clgn.jpg"
<a href="https://2009.igem.org/Team:METU-Gene/Biomaterial_Search"><img src="https://static.igem.org/mediawiki/2009/a/a1/Clgn.jpg"
     style="width:30%; height:30%; border:0px solid #aaa; margin:-10px 5px 10px 0px;">
     style="width:30%; height:30%; border:0px solid #aaa; margin:-10px 5px 10px 0px;">
 +
</html>
-
<div align="center" style="width: 700px; margin-left: 20px; float:left;"> <html><!-- main content div --></html>
 
-
<!-- close main item -->
+
== Biomaterials Modelling ==
-
----
+
 +
<div align="left">
 +
<br>'''Characterization of the rhEGF-collagen sponges'''
-
== Biomaterials Modelling ==
+
<div align="center">[1]'''Determination of the degree of crosslinking'''</div>
-
 
+
-
'''Characterization of the rhEGF-collagen sponges'''
+
-
<br align="center">[1]'''Determination of the degree of crosslinking'''
+
-
The crosslinking degree could then be obtained from the
+
<br>The crosslinking degree could then be obtained from the differences between the absorbance values before and after
-
differences between the absorbance values before and after
+
the crosslinking. The equation is as follows:
the crosslinking. The equation is as follows:
Line 43: Line 66:
where s is the sample and ncl is non-crosslinked.
where s is the sample and ncl is non-crosslinked.
-
<br align="center">[2]'''Water-binding capacity'''
+
<div align="center">[2]'''Water-binding capacity'''</div>
-
The water uptake of the collagen sponges was calculated using
+
<br>The water uptake of the collagen sponges was calculated using the following equation:
-
the following equation:
+
https://static.igem.org/mediawiki/2009/a/a3/Formul2.jpg
https://static.igem.org/mediawiki/2009/a/a3/Formul2.jpg
-
where Wd is the weight of the dry sponge and Ws is the
+
where Wd is the weight of the dry sponge and Ws is the weight of the swollen sponge.
-
weight of the swollen sponge.
+
-
<br align="center">[3]'''Release kinetics'''
+
<div align="center">[3]'''Release kinetics'''</div>
-
To determine the possible release mechanism, drug release
+
<br>To determine the possible release mechanism, drug release from collagen sponges was fitted to the following power model:
-
from collagen sponges was fitted to the following power
+
-
model:
+
https://static.igem.org/mediawiki/2009/6/64/Formul3.jpg
https://static.igem.org/mediawiki/2009/6/64/Formul3.jpg
-
where Mt/M is the fractional drug release percentage at
+
where Mt/M is the fractional drug release percentage at time t, and k is a constant related to the properties of the
-
time t, and k is a constant related to the properties of the
+
drug delivery system and n is the diffusional exponent which characterizes the drug transport mechanism.
-
drug delivery system and n is the diffusional exponent
+
-
which characterizes the drug transport mechanism.
+
 +
<!-- ***** New entry ***** -->
 +
<div class="main_item"> 
 +
<h2>Recombinant hEGF released from collagen sponges</h2>
 +
<table>
 +
<tr>
 +
<td style="padding-right:20px;">
 +
<html><div align="center" style="padding-left: 66px; padding-top: 8px;"><img style="border: 0px solid ; width: 250px; height: 250px;" alt="w6" src="https://static.igem.org/mediawiki/2009/8/8e/Figure1.jpg"></a></div></html>
 +
</td>
 +
<td>
 +
<p style="font-size:110%; color:#576f91; font-family:georgia,serif;"><br>Figure 1 shows the release profiles of rhEGF from collagen sponge at 37 �C in PBS with/without collagenase solution.
 +
<br>
 +
Chih-Hui Yang in his study supposed that under the in vitro non-degradation conditions, rhEGF was initially released by diffusion. Generally speaking, since collagen is enzymatically degraded, low final release values are expected in the absence of any enzymes. Therefore, collagenase was employed for the model of the in vitro rhEGF release study. In project, this case is also valuable.
-
Recombinant hEGF release from collagen sponges
+
<br>Therefore, the influence of the types and the concentrations of the crosslinking agents and the preparation conditions on the structures and characteristics of collagen sponges, and the rhEGF release from collagen sponges were compared in his study.</p>
-
Figure 1 shows the release profiles of rhEGF from collagen
+
</td>
-
sponge at 37 �C in PBS with/without collagenase solution.
+
</tr>
 +
</table>
 +
</div> <!-- close main item -->
-
https://static.igem.org/mediawiki/2009/8/8e/Figure1.jpg
 
-
Chih-Hui Yang in his study supposed that
+
<!-- ***** New entry ***** -->
-
under the in vitro non-degradation conditions, rhEGF was
+
<div class="main_item"> 
-
initially released by diffusion. Generally speaking, since
+
<h2>The rhEGF release patterns from collagen sponges </h2>
-
collagen is enzymatically degraded, low final release values
+
<table>
-
are expected in the absence of any enzymes. Therefore,
+
<tr>
-
collagenase was employed for the model of the in vitro
+
<td style="padding-right:20px;">
-
rhEGF release study.
+
<html><div align="center" style="padding-left: 66px; padding-top: 8px;"><img style="border: 0px solid ; width: 250px; height: 250px;" alt="w6" src="https://static.igem.org/mediawiki/2009/b/b0/Figure2.jpg"></a></div></html>
-
In project, this case is also valuable.
+
</td>
 +
<td>
 +
<p style="font-size:110%; color:#576f91; font-family:georgia,serif;"><br><br>Three different types of crosslinking agents, GTA, genipin and ECD were used to prepare crosslinked collagen sponges. The rhEGF release patterns from collagen sponges are shown in Figure 2.
-
<br>Therefore, the influence of the types and the
 
-
concentrations of the crosslinking agents and the preparation
 
-
conditions on the structures and characteristics of
 
-
collagen sponges, and the rhEGF release from collagen sponges were compared in his study.
 
-
<br>Three different
 
-
types of crosslinking agents, GTA, genipin and ECD were
 
-
used to prepare crosslinked collagen sponges. The rhEGF
 
-
release patterns from collagen sponges are shown in Figure 2.
 
-
https://static.igem.org/mediawiki/2009/b/b0/Figure2.jpg
+
The drug release rate from crosslinked collagen sponges treated with EDC was the fastest, followed by collagen sponges treated with genipin and GTA, respectively. The EDC crosslinked collagen showed no release control effect,
 +
which was probably due to the fact that EDC increased the water-solubility and lowered the viscosity of collagen (data
 +
not shown). GTA crosslinked collagen showed the most potent release control effect than the other two (EDC and genipin). '''However, since we want controlled and orderly release system which will be improved our transgenic bacteria, we used genipin for formation our cellulose Wound Dressing layer in three different types of crosslinking agents, GTA, genipin and ECD.'''</p>
-
The drug release rate from crosslinked collagen sponges
+
</td>
-
treated with EDC was the fastest, followed by collagen
+
</tr>
-
sponges treated with genipin and GTA, respectively. The
+
</table>
-
EDC crosslinked collagen showed no release control effect,
+
</div> <!-- close main item -->
-
which was probably due to the fact that EDC increased the
+
-
water-solubility and lowered the viscosity of collagen (data
+
-
not shown). GTA crosslinked collagen showed the most
+
-
potent release control effect than the other two (EDC and
+
-
genipin). '''However, since we want controlled and orderly release system which will be improved our transgenic bacteria, we used genipin for formation our cellulose Wound Dressing layer in three different types of crosslinking agents, GTA, genipin and ECD.'''
+
 +
 +
 +
 +
 +
 +
 +
<!-- close main item --></div>
== Conclusion ==
== Conclusion ==
<html>
<html>
-
<div  style="padding-left: 66px; padding-top: 8px;"><a href="https://2009.igem.org/METU-gene/Human_Practice"><img style="border: 0px solid ; width: 900px; height: 500px;" alt="w6" src="https://static.igem.org/mediawiki/2009/a/a3/Gelatincollagen.jpg"></a></div>
+
<div  style="padding-left: 25px; padding-top: 8px;"><a href="https://2009.igem.org/METU-gene/Human_Practice"><img style="border: 0px solid ; width: 900px; height: 500px;" alt="w6" src="https://static.igem.org/mediawiki/2009/a/a3/Gelatincollagen.jpg"></a></div>
</html>
</html>
 +
 +
 +
 +
 +
 +
<html><div align="center" style="margin:15px 0px 0px 0px">
 +
<a href="https://2009.igem.org/Team:METU-Gene"><img style="border: 0px solid ; width: 100px; height: 100px;" alt="w7" src="https://static.igem.org/mediawiki/2009/5/5f/Home-icon.jpg"></a></div>
 +
 +
<html>

Latest revision as of 22:45, 21 October 2009


Contents

Wound Dressing Mechanism

w7




Wound Dressing Layer Design

Rapid and proper healing is important in the treatment of wounds such as severe burns, trauma, diabetic,decubitus and venous stasis ulcers, and similar tissue damages. In cases of severe and large amounts of skin loss, or in the presence of difficult and non-healing wounds, immediate coverage of the wound surface with a dressing is needed. The dressing achieves the functions of the natural skin by protecting the area from the loss of fluid and proteins, preventing infection through bacterial invasion, and subsequent tissue damage. In some cases, it improves healing by providing a support for the proliferating cells.


Biomaterials Modelling


Characterization of the rhEGF-collagen sponges

[1]Determination of the degree of crosslinking


The crosslinking degree could then be obtained from the differences between the absorbance values before and after the crosslinking. The equation is as follows:

Formul1.jpg

where s is the sample and ncl is non-crosslinked.

[2]Water-binding capacity


The water uptake of the collagen sponges was calculated using the following equation:

Formul2.jpg

where Wd is the weight of the dry sponge and Ws is the weight of the swollen sponge.

[3]Release kinetics


To determine the possible release mechanism, drug release from collagen sponges was fitted to the following power model:

Formul3.jpg

where Mt/M is the fractional drug release percentage at time t, and k is a constant related to the properties of the drug delivery system and n is the diffusional exponent which characterizes the drug transport mechanism.

Recombinant hEGF released from collagen sponges

w6


Figure 1 shows the release profiles of rhEGF from collagen sponge at 37 �C in PBS with/without collagenase solution.
Chih-Hui Yang in his study supposed that under the in vitro non-degradation conditions, rhEGF was initially released by diffusion. Generally speaking, since collagen is enzymatically degraded, low final release values are expected in the absence of any enzymes. Therefore, collagenase was employed for the model of the in vitro rhEGF release study. In project, this case is also valuable.
Therefore, the influence of the types and the concentrations of the crosslinking agents and the preparation conditions on the structures and characteristics of collagen sponges, and the rhEGF release from collagen sponges were compared in his study.


The rhEGF release patterns from collagen sponges

w6



Three different types of crosslinking agents, GTA, genipin and ECD were used to prepare crosslinked collagen sponges. The rhEGF release patterns from collagen sponges are shown in Figure 2. The drug release rate from crosslinked collagen sponges treated with EDC was the fastest, followed by collagen sponges treated with genipin and GTA, respectively. The EDC crosslinked collagen showed no release control effect, which was probably due to the fact that EDC increased the water-solubility and lowered the viscosity of collagen (data not shown). GTA crosslinked collagen showed the most potent release control effect than the other two (EDC and genipin). However, since we want controlled and orderly release system which will be improved our transgenic bacteria, we used genipin for formation our cellulose Wound Dressing layer in three different types of crosslinking agents, GTA, genipin and ECD.





Conclusion

w6



w7